Azienda Ospedaliera Papa Giovanni XXIII
- Address
- Piazza Oms 1, 24127 Bergamo, Italy
Hematologic Malignancies and Cellular Immunotherapy
At Azienda Ospedaliera Papa Giovanni XXIII in Bergamo, research in hemic and lymphatic diseases and neoplasms is strongly focused on blood cancers. Studies are exploring new immune-based and targeted approaches for large B-cell lymphoma, relapsed or refractory non-Hodgkin’s lymphoma, acute myeloid leukemia, chronic myelomonocytic leukemia, and acute lymphoblastic leukemia, with the goal of improving treatment effectiveness and safety in difficult-to-treat disease.
- Testing novel therapies for relapsed or refractory lymphoma and leukemia
- Evaluating immune-based treatment combinations for better cancer control
- Assessing new options for patients with limited standard treatment choices
These trials reflect a broad effort to advance hematology-oncology care through more precise and potentially more effective therapies.
Solid Tumors and Precision Oncology
The site also contributes to research in neoplasms affecting the breast, stomach, lung, and skin. Clinical trials are studying locally advanced or metastatic breast cancer, gastric or gastroesophageal cancer, unresectable non-small cell lung cancer, and melanoma, often with an emphasis on tailored treatment strategies and improved outcomes after standard therapy.
- Exploring new treatment approaches for advanced breast cancer and gastric cancer
- Evaluating immunotherapy combinations in non-small cell lung cancer
- Studying patient preferences for different treatment delivery methods in melanoma
These studies aim to refine cancer care by testing whether newer therapies can better control disease and support personalized treatment decisions.
Cardiometabolic and Kidney Disease Research
Clinical trials in cardiovascular diseases, nutritional and metabolic diseases, and metabolism address common chronic conditions with major long-term impact. Research includes heart failure, heart failure with preserved ejection fraction, type 2 diabetes, and chronic kidney disease with high proteinuria, focusing on better disease control and slowing progression.
- Testing new therapies for heart failure and HFpEF
- Comparing treatments to improve blood sugar control in type 2 diabetes
- Studying approaches to slow kidney function decline in chronic kidney disease
This research supports efforts to improve everyday management of chronic cardiometabolic illness and reduce complications over time.
Immune-Mediated, Transplant, and Rare Disease Studies
Work in immune system diseases includes trials for chronic graft versus host disease, while additional studies address rare conditions such as severe Crigler-Najjar syndrome. The research also connects to broader metabolic and virus diseases interests, showing a diverse portfolio beyond oncology and cardiology.
- Evaluating new options for chronic graft versus host disease
- Investigating gene therapy for a rare inherited liver disorder
- Assessing treatments for patients with limited established therapies
These studies aim to improve symptom control, disease management, and long-term outcomes in conditions that often require specialized care.
Respiratory and Viral Disease Research
At this hospital site, research also extends to respiratory tract diseases and virus diseases. Current trials include idiopathic pulmonary fibrosis and HIV, with a focus on finding better ways to slow lung decline and support effective long-term viral treatment.
- Studying therapies for idiopathic pulmonary fibrosis
- Comparing treatment strategies for people living with HIV
- Assessing whether newer options can improve disease control and quality of life
These investigations combine chronic disease management with the search for safer, more effective treatment strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 24 therapeutic areas and 15 of 446 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 413 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 110 by active trials.
- 1Merck Sharp & Dohme LLC10active
lock +109 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB21trials
lock +55 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Papa Giovanni XXIII
lock Showing 1 of 338 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 446 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 21 | Unknown | 2017-10-02 | 2026-04-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.